23 February, Geneva - The World Health Organization and the United States Agency for International Development (USAID) have released a new guide to help countries strategically and systematically scale-up the engagement of all care providers in TB prevention and care. The Guide to develop a national action plan on Public-Private Mix (PPM) – is a planning document designed to facilitate the integration of strong public-private mix (PPM) components into national TB strategic plans that are the basis for Global Fund proposals and national budgeting processes.

TB 2018 will be held on 22 July 2018 in Amsterdam, the Netherlands immediately preceding the 2018 International AIDS Conference.

November 29, 2017 - Today, the U.S. Agency for International Development (USAID) announced further action to help India in its fight against Tuberculosis (TB). India has the world's highest incidence of TB, with 2.8 million cases annually, and accounts for more than a quarter of the global TB burden. India also has the largest burden of multi-drug-resistant TB (MDR-TB) among all countries, with almost 150,000 cases every year. TB claims over 435,000 Indian lives each year, which places TB among the top ten causes of death in the country.

8 June 2017 - The USAID-funded Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program announced the launch of the QuanTB eCourse - a free, self-paced course for health professionals using QuanTB.

USAID and TB Alliance will host an event, Innovating to End TB on 14 March 2017, 12:00 PM – 6:30 PM EDT in Washington, D.C., United States.

One of the key elements of successful tuberculosis (TB) control programs is adherence to treatment, and this is a cornerstone of most international and national policies and guidelines. Non-adherence is often due to patient-related factors, but can also be a result of provider issues, such as stock-outs of TB medicines. Non-adherence results in increases in length and severity of illness, deaths, disease transmission, and drug resistance. These have economic consequences in terms of costs and loss of income for patients and their families and also costs to the health system.

Only half of patients who start treatment for drug-resistant TB (DR-TB) finish it successfully. The reasons are many, and often are related to non-medical challenges. USAID is working with patients, their supporters and frontline providers, to develop a patient-centered care package.

The U.S. Agency for International Development (USAID) released an annual report illustrating the USAID's contribution during Fiscal Year 2015 to international TB programming. USAID supported screening, diagnosis and treatment services for people affected by TB and multidrug-resistant TB.

On 22 December 2015 the White House officially released a plan to address multidrug-resistant tuberculosis (MDR-TB) domestically and internationally and to advance research on this critical public health issue through a National Action Plan for Combating Multidrug-Resistant Tuberculosis.

USAID launched a patient-centered outpatient approach to TB care in the Kyrgyz Republic’s most populous and TB-affected region.